|
Diabetes Technology & Therapeutics
Precipitation of Insulin Products Used for Continuous Subcutaneous Insulin Infusion
To cite this article:
Christian Poulsen, Lotte Langkjær, Carsten Worsøe.
Diabetes Technology & Therapeutics.
February 2005,
7(1): 142-150.
doi:10.1089/dia.2005.7.142.
Christian Poulsen, M.Sc.Department of Pharmaceutics, Ba., Novo Nordisk A/S, Bagsvaerd, Denmark. Lotte Langkjær, M.Sc.Department of Pharmaceutics, Ba., Novo Nordisk A/S, Bagsvaerd, Denmark. Carsten Worsøe, M.Sc.Department of Protein Chemistry, Ba., Novo Nordisk A/S, Bagsvaerd, Denmark. Background: Commercially available insulin products used for continuous subcutaneous insulin infusion have been compared with respect to resistance towards isoelectric insulin precipitation. Methods: The degree of isoelectric insulin precipitation of insulin aspart injection (IAsp), insulin lispro injection (ILis), and buffered human regular insulin injection (BHR) was examined while reducing pH through addition of diluted HCl or exposure to CO2. Results: The pH at which defined fractions of the insulins precipitated differed among the three products; 10% and 90% precipitation, respectively, was observed at pH 6.41 and pH 6.30 for ILis, pH 6.18 and pH 5.95 for BHR, and pH 5.90 and pH 5.67 for IAsp, in accordance with the isoelectric points of these insulin species. The amount of H+-equivalents per microliter of product to reach 10% precipitation was found to be highest for IAsp (5.49 nmol of H+-equivalents), with ILis and BHR almost equivalent to each other (4.46 and 4.32 nmol of H+-equivalents, respectively). Exposure to a CO2-enriched environment resulted in the same order of insulin precipitation of the three products as tested with HCl. Conclusions: Resistance towards isoelectric precipitation is highest for IAsp, lowest for ILis, and intermediate for BHR. Isoelectric precipitation will alter the pharmacokinetic properties of the insulin and could lead to occlusion of the infusion catheter, causing elevated blood glucose and ultimately causing diabetic ketoacidosis if no intervention is made. Causal relationships between the observed differences in resistance towards isoelectric precipitation of the insulin products, the mechanism behind catheter occlusion, and the clinical relevance of the observations require further studies.  This paper was cited by:Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glulisine Reinhard H A Becker, Annke D Frick Clinical Pharmacokinetics. Feb 2008, Vol. 47, No. 1: 7-20 CrossRef Insulin aspart: rapid control for postmeal glucose excursions Jens Sandahl Christiansen Expert Review of Endocrinology & Metabolism. Oct 2007, Vol. 2, No. 5: 587-597 CrossRef Precipitation of Insulin Aspart and Insulin Glulisine Products Used for Continuous Subcutaneous Insulin Infusion Christian Poulsen, Lotte Langkjær, Carsten Worsøe Diabetes Technology & Therapeutics. Feb 2007, Vol. 9, No. 1: 26-35 Abstract | Full Text PDF | Reprints & PermissionsIn Vitro Stability of Insulin Lispro in Continuous Subcutaneous Insulin Infusion Michael R. DeFelippis, Maureen A. Bell, Jennifer A. Heyob, Sacha M. Storms Diabetes Technology & Therapeutics. Jun 2006, Vol. 8, No. 3: 358-368 Abstract | Full Text PDF | Reprints & PermissionsSafety and side effects of the insulin analogues Ali D Kamal, Anthony N Dixon, Stephen C Bain Expert Opinion on Drug Safety. Feb 2006, Vol. 5, No. 1: 131-143 CrossRef
|
|